SS-31 (elamipretide): what the trials show
Reviewed 21 sourcesPublished by PepVault
SS-31 (elamipretide) binds cardiolipin inside mitochondria: what it does, its 2025 FDA approval in Barth syndrome, and where the larger trials fell short.

- Last reviewed
- Sources
- 21
- Questions
- 10
- Compounds
- 2
The short answer
SS-31, sold as elamipretide (Forzinity), is a four-amino-acid peptide that binds cardiolipin, a fat found only in the inner membrane of mitochondria, where cells make their energy. The FDA gave it accelerated approval in September 2025 to improve muscle strength in Barth syndrome, a rare genetic disease, on a 12-patient trial. Its larger trials, in mitochondrial myopathy, heart failure and dry macular degeneration, missed their main goals.
Evidence: Mixed: an FDA accelerated approval in Barth syndrome built on 12 patients and an open-label extension; randomized trials in mitochondrial myopathy, heart failure and dry macular degeneration missed their main endpoints; the mechanism comes from cell and animal studies.

What is SS-31?
SS-31 is one of the Szeto-Schiller (SS) peptides, a family of small peptides that home in on the inner membrane of mitochondria, the structures inside cells that turn food and oxygen into usable energy1. Its drug name is elamipretide, its early trials called it MTP-13114, and Stealth BioTherapeutics develops it4.
The molecule is four amino acids long, D-Arg-Dmt-Lys-Phe-NH2: one of the four, 2,6-dimethyltyrosine (Dmt), is a modified form of tyrosine, and the arginine is the mirror-image D form2. The label gives its weight as 749.2 as the hydrochloride salt2. Picture a string of four beads that alternates ring-shaped and positively charged links, which is why trial papers call it an aromatic-cationic peptide8.
Peptide SkySee SS-31 as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky
What does SS-31 do in the mitochondria?
Mitochondria have two membranes. The inner one is folded into ridges called cristae, and that is where the cell makes most of its ATP, its energy currency. A fat called cardiolipin is found only in that inner membrane. It holds the folds in shape and keeps the energy-making complexes packed together so they work as a chain1.
Cardiolipin also decides what a protein called cytochrome c does: carry electrons along the chain, its normal job, or act as a peroxidase, an enzyme that oxidizes fats. Oxidized and depleted cardiolipin turns up in many conditions where cells run short of energy1. SS-31 binds cardiolipin through electric charge and water-repelling (hydrophobic) contacts. By sitting there, it stops cardiolipin from switching cytochrome c into that damaging mode, keeps its electron-carrying job intact, and protects the shape of the cristae1. The FDA label puts it in one line: a cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial shape and function2.

That mechanism comes from cell and animal studies, which is where most of SS-31's research sits1. Results in cells and animals often don't carry over to people, which is why the human trials below matter more.
Is elamipretide FDA-approved?
Yes, for one use. The FDA approved Forzinity (elamipretide) on September 19, 2025, as a new molecular entity under application NDA 215244, sponsored by Stealth BioTherapeutics3. The label's indication reads: "to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg"2.
It is an accelerated approval. That means the FDA approved it on an intermediate measure, here knee extensor muscle strength, rather than on a proven clinical benefit, and keeping the approval may depend on a confirmatory trial2. Stealth's confirmatory trial, 4TAZPower, is recruiting: about 48 people with Barth syndrome on elamipretide or placebo for 72 weeks, scored on a walk test, a timed get-up-and-go test and a sit-to-stand test combined, with results expected around 202918. It is the first treatment approved for Barth syndrome itself4.
What did the Barth syndrome trial find?
Barth syndrome is a rare inherited disease, passed on the X chromosome, in which a faulty TAZ gene leaves the body unable to build normal cardiolipin45. It affects the heart and muscles47. A drug that binds cardiolipin was a logical match.
TAZPOWER enrolled 12 people. In the first part, each spent 12 weeks on 40 mg a day of elamipretide and 12 weeks on placebo, in random order, with neither patients nor doctors told which was which. Neither main goal improved, the 6-minute walk test (how far someone walks in six minutes) or a fatigue score5. Ten then continued on open-label elamipretide, meaning everyone knew they were on the drug. The eight who reached week 36 walked 95.9 m farther and their symptom score improved5. Eight reached week 168, still 96.1 m ahead of where the open-label part began6. Compared with 19 untreated patients from a natural-history record, the 8 treated patients walked 79.7 m farther at week 647.
| Point in the trial | Patients | Median change in knee strength |
|---|---|---|
| Placebo, week 12 | 12 | -5 newtons |
| Elamipretide, week 12 | 12 | +4 newtons |
| Open-label, week 24 | 9 | +68 newtons |
| Open-label, week 168 | 8 | +63 newtons |

That strength measure is what the approval rests on. The label states plainly that elamipretide was not better than placebo on the randomized trial's two main endpoints and that the strength gains appeared only in the open-label extension2. The median starting strength was 124 newtons2.
Did it work in mitochondrial myopathy?
Primary mitochondrial myopathy is a group of genetic diseases in which faulty mitochondria leave muscles weak and quick to tire. It was SS-31's biggest test, and the results faded as the trials grew.
- MMPOWER (2018): 36 adults, a 2-hour IV infusion daily for 5 days. On the highest dose people walked 64.5 m farther, against 20.4 m on placebo, a difference that just missed statistical significance (p = 0.053), with a dose-dependent rise across doses8.
- MMPOWER-2 (2020): 30 adults, 40 mg a day under the skin for 4 weeks, crossed over with placebo. The walk gain of 19.8 m was not significant, though fatigue scores improved9.
- MMPOWER-3 (2023): the phase 3 trial, 218 adults, 40 mg a day for 24 weeks. The walk test differed from placebo by -3.2 m, and fatigue did not improve either. It missed both main goals10.
- After MMPOWER-3: people whose disease came from nuclear DNA (genes outside the mitochondria) walked farther in a planned subgroup. In a later, unplanned (post hoc) analysis, those with faults in the genes that maintain mitochondrial DNA, most of that group, gained 25.2 m against 2.0 m on placebo, a trend short of significance (p = 0.06)11. Stealth then ran NuPower, a 48-week phase 3 at 60 mg a day in that group. It finished in December 2024, and no results are posted on ClinicalTrials.gov or published on PubMed as of November 202612.
What about the heart, aging muscle and the eye?
| Trial | Who | What it found |
|---|---|---|
| EMBRACE STEMI (2016)14 | Heart attack patients during a stent procedure, one IV dose | Did not shrink heart damage on its main measure |
| Daubert (2017)20 | 36 people with heart failure, one 4-hour infusion | Smaller heart volumes at the end of the infusion on the top dose; safe |
| PROGRESS-HF (2020)13 | 71 people with heart failure, 4 or 40 mg a day for 4 weeks | No change in heart volume or pumping |
| Roshanravan (2021)15 | 39 adults aged 60 to 85, one infusion | Muscle energy capacity rose right after the dose, gone by day 7; no change in fatigue resistance |
| LHON eye drops (2024)19 | 12 people with an inherited optic nerve disease | Missed its vision goal |
| ReCLAIM-2 (2025)16 | 176 people with dry macular degeneration, 40 mg a day for 48 weeks | Missed both main goals; slower loss of the light-sensing layer |
The eye result is the one Stealth is following. In ReCLAIM-2, elamipretide slowed full loss of the ellipsoid zone, a layer on retinal scans that tracks the light-sensing cells, by 43% against placebo, a nominal result outside the main goals16. That layer is now the main endpoint of ReNEW, a phase 3 trial of 313 people on 40 mg a day for 96 weeks, with primary results expected around August 202717.
How was it given in the trials?
The label dose for Barth syndrome is 40 mg injected under the skin once a day, in the belly or outer thigh with the site rotated daily; it is halved to 20 mg in severe kidney impairment without dialysis2. It reaches its peak in the blood 30 to 60 minutes after the injection and is cleared in the urine within about 48 hours2. Most of the long trials used the same 40 mg a day591016.
Community protocols run far smaller amounts, usually a few milligrams a day. The closest any trial came is PROGRESS-HF's 4 mg arm, which did no better than placebo in heart failure13. The SS-31 Dose Guide at pepvault.app/lab/dosage/ss-31 lists the community range beside the label dose, and the calculator pages at pepvault.app/tools/reconstitution-calculator/ss-31-10mg and /ss-31-50mg show how a powdered vial is mixed.
These are the amounts the trials and the label used for specific diseases, under medical care, not a protocol to copy.
What side effects did the trials see?
Injection-site reactions are the main one, and nearly everyone gets them. In the Barth trial all 12 patients had redness at the site on elamipretide, against 3 of 12 on placebo; 67% had hardening or itching and 75% had pain2. In MMPOWER-2, 80% had site reactions, most of them mild9. The label's own advice is to rotate the site every day and skip skin that is tender, bruised, red or hard2.
In the PepVault app, each logged shot asks where it went, so you can rotate sites, and a daily reminder comes at the time you choose. Log it in PepVault
The label notes two more. Eosinophils, a type of white blood cell, often rose in courses of a month or more, peaked around day 90 and returned to normal within 6 to 12 months, with no symptoms attached2. And allergic reactions have been reported, some needing emergency care; the label asks doctors to watch for them2. In MMPOWER-3 most side effects were mild to moderate10.
Commonly reported: red, itchy welts at the injection site, very common, and for some, steadier stamina with less of a crash after exercise, building over weeks rather than in days.
When to get help If signs of an allergic reaction appear, such as a rash or a cough, the label's advice is to stop the drug and get medical help right away2.
SS-31 or MOTS-c?
Both are called mitochondrial peptides, but they work from different sides. SS-31 is a drug-like molecule that sits on cardiolipin inside the membrane. MOTS-c is a 16-amino-acid peptide written in the mitochondria's own DNA, which acts as a signal: in mice it works through the AMPK energy-sensing pathway and prevented diet-induced insulin resistance21. SS-31 has the approval and the large human trials; MOTS-c's evidence is mostly in mice and cells. The side-by-side is at pepvault.app/peptides/compare/mots-c-vs-ss-31.
Where to read more
- The library page, pepvault.app/peptides/ss-31, with its side effects, stacks and legal status pages.
- Most of the trials above have a study page, such as pepvault.app/research/ss-31-mmpower-3-2023 and pepvault.app/research/ss-31-tazpower-2024.
- Accelerated approval, open-label and post hoc analysis are explained at pepvault.app/glossary/accelerated-approval, /glossary/open-label and /glossary/post-hoc-analysis.
- Next guide: BPC-157, the human data we have.
Sources
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. PubMed 24117165
- FORZINITY (elamipretide) injection, prescribing information. Stealth BioTherapeutics. DailyMed, revised November 2026. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. Drugs@FDA: NDA 215244, Forzinity, original approval September 19, 2025 (Type 1, new molecular entity). accessdata.fda.gov
- Shirley M. Elamipretide: First Approval. Drugs. 2026. PubMed 41335372
- Reid Thompson W, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021. PubMed 33077895
- Thompson WR, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024. PubMed 38602181
- Hornby B, et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022. PubMed 36056411
- Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018. PubMed 29500292
- Karaa A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020. PubMed 32096613
- Karaa A, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023. PubMed 37268435
- Karaa A, et al. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024. PubMed 39574155
- ClinicalTrials.gov. NCT05162768: NuPower, elamipretide in primary mitochondrial disease from nuclear DNA mutations. Sponsor: Stealth BioTherapeutics Inc. clinicaltrials.gov
- Butler J, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020. PubMed 32068002
- Gibson CM, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016. PubMed 26586786
- Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021. PubMed 34264994
- Ehlers JP, et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmol Sci. 2025. PubMed 39605874
- ClinicalTrials.gov. NCT06373731: ReNEW, phase 3 of subcutaneous elamipretide in dry age-related macular degeneration. Sponsor: Stealth BioTherapeutics Inc. clinicaltrials.gov
- ClinicalTrials.gov. NCT07531251: 4TAZPower, phase 3b/4 confirmatory trial of elamipretide in Barth syndrome. Sponsor: Stealth BioTherapeutics Inc. clinicaltrials.gov
- Karanjia R, Sadun AA. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology. 2024. PubMed 37923251
- Daubert MA, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017. PubMed 29217757
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PubMed 25738459
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.